Clinical experience demonstrates the feasibility and safety of teplizumab in stage 2 type 1 diabetes, highlighting its multidisciplinary approach.
Teplizumab administration under compassionate use proved feasible and safe in a real-life academic context, consistent with pivotal trial data. The experience underscores the importance of a structured multidisciplinary approach, integrating endocrinologists, anaesthesiologists, nurses and psychologists to optimise adherence, safety and patient engagement during early disease-modifying immunotherapy in presymptomatic T1D.
No takes yet. Share an insight, caveat, or question.
Guarnotta et al. (2026) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: